Cytokinetics to present positive Phase 3 trial results of aficamten for non-obstructive hypertrophic cardiomyopathy at ESC 2026

Cytokinetics announced three late-breaking science abstracts at the European Society of Cardiology (ESC) Congress 2026, including a Hot Line presentation of primary results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy (HCM). The trial showed positive topline results, and the company plans to discuss these with regulatory authorities like the FDA. Cytokinetics will also host an investor event to discuss these findings. This is significant as aficamten is already approved for obstructive HCM and could expand treatment options for non-obstructive HCM patients.